The Gen Z ETF (ZGEN)
- Previous Close
12.28 - Open
11.69 - Bid --
- Ask --
- Day's Range
12.01 - 12.01 - 52 Week Range
9.97 - 13.38 - Volume
2 - Avg. Volume
0 - Net Assets 1.32M
- NAV 12.09
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return 16.04%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.63%
The fund is an actively managed ETF that will invest its assets in U.S.-listed equity securities of companies that, in the assessment of the Sub-Adviser (Alkali Fintech LLC), are the most relevant to Generation Z. Gen Z is the largest generation to date with well over 2 billion members. Gen Z is forecasted to become the highest earning generation within a decade. Historically, technology has been most rapidly adopted by younger, emerging generations.
Genz ETF
Fund Family
Large Growth
Fund Category
1.32M
Net Assets
2021-12-15
Inception Date
Performance Overview: ZGEN
Trailing returns as of 3/23/2023. Category is Large Growth.
Holdings: ZGEN
Top 10 Holdings (46.21% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: ZGEN
NBIX: Lowering target price to $111.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $111.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetNBIX: What does Argus have to say about NBIX?
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $115.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetNBIX: Raising target price to $115.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $115.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetNBIX: Lowering target price to $114.00
NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $114.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice Target